Analyzing Daxor (NASDAQ:DXR) & RadNet (NASDAQ:RDNT)

RadNet (NASDAQ:RDNT) and Daxor (NASDAQ:DXR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Profitability

This table compares RadNet and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RadNet	-0.65%	2.52%	0.87%
Daxor	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for RadNet and Daxor, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1	1	5	2	2.89
Daxor	0	1	2	0	2.67

RadNet presently has a consensus price target of $90.33, indicating a potential upside of 28.13%. Daxor has a consensus price target of $25.00, indicating a potential upside of 103.09%. Given Daxor’s higher probable upside, analysts plainly believe Daxor is more favorable than RadNet.

Volatility and Risk

RadNet has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Daxor has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.

Insider & Institutional Ownership

77.9% of RadNet shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 5.6% of RadNet shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares RadNet and Daxor”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$1.83 billion	2.97	$2.79 million	($0.17)	-414.71
Daxor	N/A	N/A	N/A	N/A	N/A

RadNet has higher revenue and earnings than Daxor.

Summary

RadNet beats Daxor on 8 of the 11 factors compared between the two stocks.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.